Our first round-up of October 2024 medical device regulatory updates includes new CLSI guidelines and an upcoming webinar in the US, new MDCG guidance documents in Europe, and new industry standards from the NMPA in China.
The Clinical and Laboratory Standards Institute (CLSI) has released the first edition of EP47, Evaluation of Reagent Carryover Effects on Test Results. Published on September 11, this document offers detailed guidance for developers and laboratories on how to assess and mitigate reagent carryover during in vitro diagnostic tests. EP47 aims to standardize the evaluation process across the industry, helping ensure accurate and reliable test results by addressing potential carryover risks.
Join the webinar hosted by the Clinical and Laboratory Standards Institute (CLSI), which is highlighting the latest method evaluation standards. This session will feature discussions on the framework of CLSI EP standards, an overview of EP10 for quantitative medical laboratory procedures, and a preview of the newly released EP47 guideline on reagent carryover.
Date: November 12, 2024
Time: 1:00 PM ET
Speakers:
- Mark Kellogg, PhD, MT(ASCP), DABCC (Moderator)
- Paula Ladwig, MS, MLS(ASCP)
- Michelle Campbell, MS, MLS(ASCP)CMMBCM, SCCM
- Marvin Berman, PhD
- Tabitha Kern, MS, MLS(ASCP)CM
Link to Register: [CLSI Webinar: What's New in Method Evaluation]
Learn more about FDA US Medical Device Registration.
Published by the EU Directorate-General for Health and Food Safety on October 7, 2024, this guidance document provides essential instructions for conformity assessment bodies (CABs), notified bodies (NBs), designating authorities (DAs), and joint assessment teams (JATs) involved in MDR and IVDR regulations. It covers the establishment and review of corrective and preventive action (CAPA) plans to address non-compliances found during joint assessments, aiming to streamline the review process with structured templates for effective communication.
Published by the EU Directorate-General for Health and Food Safety in October 2024, this guidance document clarifies the qualification criteria for products under Regulation 2017/746 (IVDR). It defines the scope of in vitro diagnostic medical devices (IVDs) and their accessories, focusing on the distinction between IVDR and MDR regulations. The guidance includes examples of IVDs and accessories, offering manufacturers a framework for determining product qualification based on intended purpose, with reference to relevant European Commission resources.
Learn more about EU Medical Device Registration.
On October 8, 2024, the National Medical Products Administration of China announced (link in Chinese) the approval of 34 medical device industry standards, including YY 0271.2-2024, titled "Dentistry Water-based Cement Part 2: Resin-Modified Cement." This announcement includes details on the standard numbers, names, scope of application, and implementation dates, which are available in the attached Medical Device Industry Standard Information Table. For more information, please refer to the annex provided.
Learn more about China Medical Device Registration & Approval.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.